KOOL - セスカ・セラピュ―ティクス (Cesca Therapeutics Inc.) セスカ・セラピュ―ティクス

 KOOLのチャート


 KOOLの企業情報

symbol KOOL
会社名 Cesca Therapeutics Inc (セスカ・セラピュ―ティクス)
分野(sector) Capital Goods   資本財(工業製品)
産業(industry) Medical Specialities  
業種 医薬品   医療関連(Health Care)
概要 事業概要 セスカ・セラピオティックス(Cesca Therapeutics Inc)(旧称:ThermoGenesis Corp.)は再生医療実践に使用する細胞と組織治療の処理・保存・管理ためのデバイス・使い捨て工具を設計・開発・商品化する。同社の製品は実験室とポイントオブケア治療での使用のために臍帯血と骨髄から成体幹細胞濃縮液の容積減少と凍結保存過程を自動化する。同社は世界中の約30カ国において私用・公共臍帯血バンク、外科医、病院及び研究機関などの顧客向けに製品を販売する。同社は臍帯血、末梢血と骨髄など体液の保存に行われる細胞分離・処理・凍結保存を可能にする製品・技術を提供する。平成26年2月、同社はTotipotentRX Corporationとの合併を完了した。   セスカ・セラピュ―ティクスは米国の医療関連会社。再生医療に使用される自家細胞治療薬の研究、開発、商業化に従事。細胞療法、医療・診断機器、細胞製造・加工システム、細胞バンクなどの市場を対象に、細胞および組織の分離、処理、保存を可能にする自動血液・骨髄処理システムを開発、製造する。   Cesca Therapeutics, Inc. engages in the research, development, commercialization and marketing of automated technologies for cell-based therapies for use in regenerative medicine. It operates through the following segments: Device and Clinical Development. The Device segment includes development and commercialization of automated systems that provide good manufacturing practice, clinical grade cell-banking, cell-processing and cell-based therapeutics. The Clinical Development segment develops autologous stem cell-based therapeutics that address significant unmet medical needs for the vascular, cardiology, and orthopedic markets. The company was founded by Philip H. Coelho in 1986 and is headquartered in Rancho Cordova, CA.
本社所在地 2711 Citrus Road Rancho Cordova CA 95742 USA
代表者氏名 Xiaochun Xu Xiaochun Xu
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 916-858-5100
設立年月日 31594
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 111人
url www.cescatherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/kool
adr_tso
EBITDA EBITDA(百万ドル) -10.50200
終値(lastsale) 0.3795
時価総額(marketcap) 7836351.2865
時価総額 時価総額(百万ドル) 7.53694
売上高 売上高(百万ドル) 9.88400
企業価値(EV) 企業価値(EV)(百万ドル) 11.66594
当期純利益 当期純利益(百万ドル) -18.24300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cesca Therapeutics Inc revenues totaled $3.9M. Net loss totaled to $29.6M. Results are not comparable due to year end change.

 KOOLのテクニカル分析


 KOOLのニュース

   The Daily Biotech Pulse: Sandoz Recalls Ulcer Drug, Anchiano Strikes Agreement With ADT Pharma, Proteon Announces Reverse Merger  2019/09/24 12:12:30 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 23.) Applied Therapeutics Inc (NASDAQ: APLT ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) ( announced a communication from the FDA allowing it to proceed with a reduced sample size in a Phase 3 study of its drug to treat excessive daytime sleepiness) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Celgene Corporation (NASDAQ: CELG ) Cesca Therapeutics Inc (NASDAQ: KOOL ) DURECT Corporation (NASDAQ: DRRX ) Enlivex Therapeutics Ltd (NASDAQ: ENLV ) Sanofi SA (NASDAQ: SNY ) SpringWorks Therapeutics Inc (NASDAQ: SWTX ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks that hit 52-week lows Sept. 23) Aduro BioTech Inc (NASDAQ: ADRO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akcea Therapeutics Inc (NASDAQ: AKCA ) (announced departures of CEO, president and COO, and the appointment of board member Damien McDevitt as interim CEO) BioNano Genomics Inc (NASDAQ: BNGO ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Cellectis SA (NASDAQ: CLLS ) Clovis Oncology Inc (NASDAQ: CLVS ) (announced acquisition of rights to FAP-targeted radiopharmaceuticals from 3B Pharmaceuticals for $12 million) Erytech Pharma SA (NASDAQ: ERYP ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Kalvista Pharmaceuticals Inc (NASDAQ: KALV ) KITOV PHARMA LT/S ADR (NASDAQ: KTOV ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Neon …
   Cesca Therapeutics Inc. (KOOL) CEO Chris Xu on Q1 2019 Results - Earnings Call Transcript  2019/05/14 23:45:04 Seeking Alpha
Cesca Therapeutics Inc. (NASDAQ:KOOL) Q1 2019 Earnings Conference Call May 14, 2019 4:30 PM ET Company Participants Paula Schwartz - Managing Director, Rx Commu
   Cesca Therapeutics EPS in-line, misses on revenue  2019/05/14 20:15:17 Seeking Alpha
Cesca Therapeutics (KOOL): Q1 GAAP EPS of -$0.08 in-line. Revenue of $2.96M (+58.3% Y/Y) misses by $0.14M. Shares +0.75%. Press Release
   Will Cesca Therapeutics (KOOL) Report Negative Q1 Earnings? What You Should Know  2019/05/06 14:30:21 Zacks Investment Research
Cesca Therapeutics (KOOL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Cesca Therapeutics Inc. (KOOL) CEO Chris Xu on Q4 2018 Results - Earnings Call Transcript  2019/03/25 23:30:08 Seeking Alpha
   The Daily Biotech Pulse: Sandoz Recalls Ulcer Drug, Anchiano Strikes Agreement With ADT Pharma, Proteon Announces Reverse Merger  2019/09/24 12:12:30 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 23.) Applied Therapeutics Inc (NASDAQ: APLT ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) ( announced a communication from the FDA allowing it to proceed with a reduced sample size in a Phase 3 study of its drug to treat excessive daytime sleepiness) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Celgene Corporation (NASDAQ: CELG ) Cesca Therapeutics Inc (NASDAQ: KOOL ) DURECT Corporation (NASDAQ: DRRX ) Enlivex Therapeutics Ltd (NASDAQ: ENLV ) Sanofi SA (NASDAQ: SNY ) SpringWorks Therapeutics Inc (NASDAQ: SWTX ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks that hit 52-week lows Sept. 23) Aduro BioTech Inc (NASDAQ: ADRO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akcea Therapeutics Inc (NASDAQ: AKCA ) (announced departures of CEO, president and COO, and the appointment of board member Damien McDevitt as interim CEO) BioNano Genomics Inc (NASDAQ: BNGO ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Cellectis SA (NASDAQ: CLLS ) Clovis Oncology Inc (NASDAQ: CLVS ) (announced acquisition of rights to FAP-targeted radiopharmaceuticals from 3B Pharmaceuticals for $12 million) Erytech Pharma SA (NASDAQ: ERYP ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Kalvista Pharmaceuticals Inc (NASDAQ: KALV ) KITOV PHARMA LT/S ADR (NASDAQ: KTOV ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Neon …
   Cesca Therapeutics Inc. (KOOL) CEO Chris Xu on Q1 2019 Results - Earnings Call Transcript  2019/05/14 23:45:04 Seeking Alpha
Cesca Therapeutics Inc. (NASDAQ:KOOL) Q1 2019 Earnings Conference Call May 14, 2019 4:30 PM ET Company Participants Paula Schwartz - Managing Director, Rx Commu
   Cesca Therapeutics EPS in-line, misses on revenue  2019/05/14 20:15:17 Seeking Alpha
Cesca Therapeutics (KOOL): Q1 GAAP EPS of -$0.08 in-line. Revenue of $2.96M (+58.3% Y/Y) misses by $0.14M. Shares +0.75%. Press Release
   Will Cesca Therapeutics (KOOL) Report Negative Q1 Earnings? What You Should Know  2019/05/06 14:30:21 Zacks Investment Research
Cesca Therapeutics (KOOL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Cesca Therapeutics Inc. (KOOL) CEO Chris Xu on Q4 2018 Results - Earnings Call Transcript  2019/03/25 23:30:08 Seeking Alpha
   The Daily Biotech Pulse: Sandoz Recalls Ulcer Drug, Anchiano Strikes Agreement With ADT Pharma, Proteon Announces Reverse Merger  2019/09/24 12:12:30 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 23.) Applied Therapeutics Inc (NASDAQ: APLT ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) ( announced a communication from the FDA allowing it to proceed with a reduced sample size in a Phase 3 study of its drug to treat excessive daytime sleepiness) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Celgene Corporation (NASDAQ: CELG ) Cesca Therapeutics Inc (NASDAQ: KOOL ) DURECT Corporation (NASDAQ: DRRX ) Enlivex Therapeutics Ltd (NASDAQ: ENLV ) Sanofi SA (NASDAQ: SNY ) SpringWorks Therapeutics Inc (NASDAQ: SWTX ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks that hit 52-week lows Sept. 23) Aduro BioTech Inc (NASDAQ: ADRO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akcea Therapeutics Inc (NASDAQ: AKCA ) (announced departures of CEO, president and COO, and the appointment of board member Damien McDevitt as interim CEO) BioNano Genomics Inc (NASDAQ: BNGO ) Catalyst Biosciences Inc (NASDAQ: CBIO ) Cellectis SA (NASDAQ: CLLS ) Clovis Oncology Inc (NASDAQ: CLVS ) (announced acquisition of rights to FAP-targeted radiopharmaceuticals from 3B Pharmaceuticals for $12 million) Erytech Pharma SA (NASDAQ: ERYP ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Kalvista Pharmaceuticals Inc (NASDAQ: KALV ) KITOV PHARMA LT/S ADR (NASDAQ: KTOV ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Neon …
   Cesca Therapeutics Inc. (KOOL) CEO Chris Xu on Q1 2019 Results - Earnings Call Transcript  2019/05/14 23:45:04 Seeking Alpha
Cesca Therapeutics Inc. (NASDAQ:KOOL) Q1 2019 Earnings Conference Call May 14, 2019 4:30 PM ET Company Participants Paula Schwartz - Managing Director, Rx Commu
   Cesca Therapeutics EPS in-line, misses on revenue  2019/05/14 20:15:17 Seeking Alpha
Cesca Therapeutics (KOOL): Q1 GAAP EPS of -$0.08 in-line. Revenue of $2.96M (+58.3% Y/Y) misses by $0.14M. Shares +0.75%. Press Release
   Will Cesca Therapeutics (KOOL) Report Negative Q1 Earnings? What You Should Know  2019/05/06 14:30:21 Zacks Investment Research
Cesca Therapeutics (KOOL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Cesca Therapeutics Inc. (KOOL) CEO Chris Xu on Q4 2018 Results - Earnings Call Transcript  2019/03/25 23:30:08 Seeking Alpha

 関連キーワード  (医薬品 米国株 セスカ・セラピュ―ティクス KOOL Cesca Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)